Research graph
References from Gas6/Axl-mediated macrophage hyporesponsiveness drives severe pulmonary mucormycosis in diabetic mice. Local targets link to admitted publications; unresolved targets remain external evidence.
Clinical phenotypes of COVID-19 associated mucormycosis (CAM): A comprehensive review
10.3390/diagnostics12123092 · 2022 · External reference
Impact of overlapping risks of type 2 diabetes and obesity on coronavirus disease severity in the United States
10.1038/s41598-021-96720-x · 2021 · External reference
Biochemistry and molecular cell biology of diabetic complications
10.1038/414813a · 2001 · External reference
IL-17-mediated immunity to the opportunistic fungal pathogen Candida albicans
10.4049/jimmunol.1500909 · 2015 · External reference
Impaired leucocyte functions in diabetic patients
10.1002/(sici)1096-9136(199701)14:1<29::aid-dia300>3.0.co;2-v · 1997 · External reference
A bittersweet response to infection in diabetes; targeting neutrophils to modify inflammation and improve host immunity
10.3389/fimmu.2021.678771 · 2021 · External reference
CARD9-dependent neutrophil recruitment protects against fungal invasion of the central nervous system
10.1371/journal.ppat.1005293 · 2015 · External reference
Immune dysfunction in patients with diabetes mellitus (DM)
10.1111/j.1574-695x.1999.tb01397.x · 1999 · External reference
Innate lymphoid cells: New players in IL-17-mediated antifungal immunity
10.1371/journal.ppat.1003763 · 2013 · External reference
The streptozotocin-induced diabetic nude mouse model: Differences between animals from different sources
2011 · External reference
The emergence of COVID-19 associated mucormycosis: A review of cases from 18 countries
10.1016/s2666-5247(21)00237-8 · 2022 · External reference
Pathogenesis of mucormycosis
10.1093/cid/cir865 · 2012 · External reference
Fungus-targeted nanomicelles enable microRNA delivery for suppression of virulence in Aspergillus fumigatus as a novel antifungal approach
10.1038/s41598-025-02742-0 · 2025 · External reference
Respiratory syncytial virus-mediated Gas6/Axl axis induces hyporesponsive macrophages to promote pneumococcal proliferation in the nasopharynx
10.1093/infdis/jiag004 · 2026 · External reference
Biology of the TAM receptors
10.1101/cshperspect.a009076 · 2013 · External reference
Growth arrest-specific factor 6 (GAS6) is increased in COVID-19 patients and predicts clinical outcome
10.3390/biomedicines9040335 · 2021 · External reference
Gas6 induces Akt/mTOR-mediated mesangial hypertrophy in diabetic nephropathy
10.1111/j.1523-1755.2005.00433.x · 2005 · External reference
Epidemiology and outcome of zygomycosis: A review of 929 reported cases
10.1086/432579 · 2005 · External reference
Host defenses against zygomycetes
10.1093/cid/cir869 · 2012 · External reference
TAM receptors are pleiotropic inhibitors of the innate immune response
10.1016/j.cell.2007.10.034 · 2007 · External reference
The development of the acute inflammatory response to experimental cutaneous mucormycosis in normal and diabetic rabbits
10.1084/jem.110.6.845 · 1959 · External reference
Axl receptor blockade protects from invasive pulmonary aspergillosis in mice
10.4049/jimmunol.1401258 · 2014 · External reference
Axl receptor blockade ameliorates pulmonary pathology resulting from primary viral infection and viral exacerbation of asthma
10.4049/jimmunol.1302766 · 2014 · External reference
Role of growth arrest-specific gene 6 in the development of fungal allergic airway disease in mice
10.1165/rcmb.2014-0049oc · 2014 · External reference
Respiratory syncytial virus infection exacerbates pneumococcal pneumonia via Gas6/Axl-mediated macrophage polarization
10.1172/jci125505 · 2020 · External reference
Epidemiology and diagnosis of mucormycosis: An update
10.3390/jof6040265 · 2020 · External reference
Histological quantification to determine lung fungal burden in experimental aspergillosis
10.3791/57155 · 2018 · External reference
Diabetes mellitus and sepsis: A challenging association
10.1097/shk.0000000000000778 · 2017 · External reference
ACCORD: A multicentre, seamless, phase 2 adaptive randomisation platform study to assess the efficacy and safety of multiple candidate agents for the treatment of COVID-19 in hospitalised patients: A structured summary of a study protocol for a randomised controlled trial
10.1186/s13063-020-04584-9 · 2020 · External reference
Streptozotocin-induced diabetic models in mice and rats
10.1002/0471141755.ph0547s40 · 2008 · External reference
Obesity and diabetes as high-risk factors for severe coronavirus disease 2019 (Covid-19)
10.1002/dmrr.3377 · 2021 · External reference
